Practice guidelines for inflammatory bowel disease: An instrument for assessment

Mayo Clinic Proceedings

Volumn 74, Issue 5, 1999, Pages 495-501

  Tremaine, William J ^a   Sandborn, William J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL FEATURE; CROHN DISEASE; ENTERITIS; FAMILY HISTORY; HUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; RISK FACTOR; SMOKING; TOBACCO; ULCERATIVE COLITIS;

EID: 0032890738     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.5.495     Document Type: Article

References (54)

1. Institute of Medicine, Committee on Clinical Practice Guidelines. Guidelines for Clinical Practice: From Development to Use. Washington (DC): National Academy Press; 1992
2. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989:321:1306-1311
3. Kornbluth A, Sachar DB (American College of Gastroenterology, Practice Parameters Committee). Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997;92:204-211
4. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997;92:559-566
5. Katz S. Keys to Diagnosis and Treatment: Inflammatory Bowel Disease; A Physician Reference Guide. Arlington (VA): American College of Gastroenterology; 1998
6. Gabrielsson N, Granqvist S, Sundelin P, Thorgeirsson T. Extent of inflammatory lesions in ulcerative colitis assessed by radiology, colonoscopy, and endoscopic biopsies. Gastrointest Radiol 1979; 4:395-400
7. Goldberg HI, Caruthers SB Jr, Nelson JA, Singleton JW. Radiographic findings of the National Cooperative Crohn's Disease Study. Gastroenterology 1979;77:925-937
8. Surawicz CM, Belie L. Rectal biopsy helps to distinguish acute selflimited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984:86:104-113
9. Bernstein CN, Boult IF, Greenberg HM, van der Putten W, Duffy G, Grahame GR. A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease. Gastroenterology 1997:113:390-398
10. Chernish SM, Maglinte DD, O'Connor K. Evaluation of the small intestine by enteroclysis for Crohn's disease. Am J Gastroenterol 1992;87:696-701
11. Gore RM. CT of inflammatory bowel disease. Radiol Clin North Am 1989 Jul;27:717-729
12. Khaw KT, Yeoman U, Saverymuttu SH, Cook MG, Joseph AE. Ultra sonic patterns in inflammatory bowel disease. Clin Radiol 1991;43:171-175
13. Waye JD. Endoscopy in inflammatory bowel disease. In: Kirsner JB, Shorter RG, editors. Inflammatory Bowel Disease. 4th ed. Baltimore: Williams & Wilkins; 1995. pp 555-582
14. Oberhuber G, Puspok A, Oesterreicher C, Novacek G, Zauner C, Burghuber M, et al. Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease. Gastroenterology 1997; 112:698-706
15. Pritchard TJ, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Perirectal abscess in Crohn's disease: drainage and outcome. Dis Colon Rectum 1990;33:933-937
16. El-Serag HB, Zwas F, Bonheim NA, Cirillo NW, Appel G. The renal and urologic complications of inflammatory bowel disease. Inflamm Bowel Dis 1997:3:217-224
17. Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990 Jan;74:21-28
18. Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981:80:697-700
19. Loftus EV Jr, Alexander GL, Carpenter HA. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol 1994; 19:306-309
20. Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995;70:55-61
21. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981:80:693-696
22. Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med 1987:316:707-710
23. Cottone M, Rosselli M, Orlando A, Oliva L, Puleo A, Cappello M, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-648
24. Walker-Smith JA. Management of growth failure in Crohn's disease. Arch Dis Child 1996;75:351-354
25. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enterai nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-1067
26. Meuwissen SGM, Crusius JBA, Pena AS, Dekker-Saeys AJ, Dijkmans BAC. Spondyloarthropathy and idiopathic inflammatory bowel diseases. Inflamm Bowel Dis 1997;3:25-37
27. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982:14:356-360
28. Tremaine WJ. Treatment of erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum in patients with IBD. Inflamm Bowel Dis 1998;4:68-69
29. Harnois DM, Lindor KD. Primary sclerosing cholangitis: evolving concepts in diagnosis and treatment. Dig Dis 1997;15:23-41
30. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995:37:71-76
31. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982;83:1252-1258
32. Malcorps J, Eekhaut M, Dierckxsens P. Bilateral stage III osteonecrosis of the femoral head treated with core decompression: case report and review of the literature. Acta Orthop Belg 1996; 62:241-243
33. Tripathi RC, Kirschner BS, Kipp M, Tripathi BJ, Slotwiner D, Borisuth NS, et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992;102:1957-1961
34. Hutchinson R, Tyrrell PN, Kumar D, Dünn JA, Li JK, Allan RN. Patho genesis of gall stones in Crohn's disease: an alternative explanation. Gut 1994;35:94-97
35. Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998;93:504-514
36. Present DH. Pregnancy and fertility in Crohn's disease. In: Prantera C, Korelitz Bl, editors. Crohn's Disease. New York: Marcel Dekker; 1996. pp 413-427
37. Schreiber S, Wedel S. Diagnosis and treatment of anemia in inflammatory bowel disease. Inflamm Bowel Dis 1997;3:204-216
38. Levenstein S. Psychosocial issues in Crohn's disease. In: Prantera C, Korelitz Bl, editors. Crohn's Disease. New York: Marcel Dekker; 1996. pp 429-443
39. Lennard-Jones JE, Connell WR. Surveillance-inflammatory bowel disease. In: Cohen AM, Winawer SJ, Friedman MA, Gunderson LL, editors. Cancer of the Colon, Rectum, and Anus. New York: McGraw-Hill; 1995. pp 359-370
40. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994:343:1249-1252
41. Drossman DA, Leserman J, Mitchell CM, Li ZM, Zagami EA, Patrick DL. Health status and health care use in persons with inflammatory bowel disease: a national sample. Dig Dis Sci 1991;36:1746-1755
42. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al (Canadian Crohn's Relapse Prevention Trial Study Group). Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-296
43. Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991;100:1638-1643
44. Yang H, Rotter Jl. Genetic aspects of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG, editors. Inflammatory Bowel Disease. 4th ed. Baltimore: Williams & Wilkins; 1995. pp 301-331
45. Steiner-Grossman P. The approach to the inflammatory bowel disease family. In: Kirsner JB, Shorter RG, editors. Inflammatory Bowel Disease. 4th ed. Baltimore: Williams & Wilkins; 1995. pp 985-994
46. Mort EA, Edwards JN, Emmons DW, Convery K, Blumenthal D. Physician response to patient insurance status in ambulatory care clinical decision-making: implications for quality of care. Med Care 1996;34:783-797
47. Sutherland LR, May GR, Shatter EA. Sulfasalazine revisited: a metaanalysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993:118:540-549
48. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994:35:360-362
49. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996:91:423-433
50. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al (Crohn's Disease cA2 Study Group). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor oc for Crohn's disease. N Engl J Med 1997:337:1029-1035
51. Tremaine WJ, Dozois RR. Inflammatory bowel disease. In: Shearman DJC, Finlayson NDC, Camilleri M, Carter DC, editors. Diseases of the Gastrointestinal Tract and Liver. 3rd ed. New York: Churchill Livingstone; 1997. pp 643-706
52. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-1473
53. Thomson AB. Review article: new developments in the use of 5aminosalicylic acid in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1991;5:449-470
54. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483